Stock Analiz

Novavax Inc. (NVAX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Novavax’s revenue went from $15M in fiscal 2016 to $1.1B in fiscal 2025, growth of about 61.1% a year.

Net income in fiscal 2025 was $440M, a net margin of 39.2%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $412M and net income -$77M.

Free cash flow was -$250M in fiscal 2025 and positive in 1 of the 10 years shown.

The diluted share count rose 1178% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $15M162017: $31M172018: $34M182019: $19M192020: $476M202021: $1.1B212022: $2.0B222023: $984M232024: $682M242025: $1.1B25$1.1B
Net income
2016: -$280M162017: -$184M172018: -$185M182019: -$133M192020: -$418M202021: -$1.7B212022: -$658M222023: -$545M232024: -$187M242025: $440M25$440M
Free cash flow
2016: -$277M162017: -$149M172018: -$186M182019: -$138M192020: -$97M202021: $265M212022: -$505M222023: -$768M232024: -$100M242025: -$250M25-$250M
EPS (diluted)
2016: $-20.60162017: $-12.56172018: $-9.99182019: $-5.51192020: $-7.27202021: $-23.44212022: $-8.42222023: $-5.41232024: $-1.23242025: $2.5825$2.58

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$412M$1.1B$682M$984M$2.0B$1.1B$476M$19M$34M$31M$15M
Gross profit$321M$1.1B$479M$640M$1.1B$1.1B$476M————
Operating income-$87M$453M-$249M-$567M-$645M-$1.7B-$417M-$121M-$174M-$172M-$269M
Net income-$77M$440M-$187M-$545M-$658M-$1.7B-$418M-$133M-$185M-$184M-$280M
EPS (diluted)$-0.52$2.58$-1.23$-5.41$-8.42$-23.44$-7.27$-5.51$-9.99$-12.56$-20.60
R&D$294M$342M$391M$738M$1.2B$2.5B$747M$114M$174M$168M$238M
Revenue growth—+64.7%−30.6%−50.4%+72.9%+141.0%+2448.5%−45.6%+10.0%+103.1%−57.6%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$239M-$245M-$87M-$714M-$416M$323M-$43M-$137M-$185M-$144M-$259M
Capital spending-$4M-$6M-$13M-$54M-$89M-$57M-$55M-$2M-$1M-$4M-$18M
Free cash flow-$243M-$250M-$100M-$768M-$505M$265M-$97M-$138M-$186M-$149M-$277M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$32M$36M$48M$85M$130M$184M$128M$17M$18M$20M$19M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$735M$923M$569M$1.3B$1.5B$711M$79M$92M$157M$235M
Debt—$29M$203M$281M$450M$201M$160M$11M——$0
Equity—-$128M-$624M-$717M-$634M-$352M$627M-$186M-$168M-$102M-$6M
Total assets—$1.2B$1.6B$1.8B$2.3B$2.6B$1.6B$173M$208M$302M$394M
Shares (diluted)165M173M152M101M78M74M58M24M18M15M14M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin78.0%93.5%70.3%65.0%54.5%100.0%100.0%————
Operating margin-21.2%40.3%-36.5%-57.6%-32.5%-147.1%-87.6%-646.1%-507.2%-550.8%-1752.8%
Net margin-18.6%39.2%-27.5%-55.4%-33.2%-152.1%-87.9%-711.0%-538.8%-589.5%-1823.5%
FCF margin-59.1%-22.3%-14.7%-78.0%-25.5%23.2%-20.4%-742.0%-543.0%-476.9%-1804.0%
ROIC——————-52.9%————
ROE—-344.6%30.1%76.0%103.8%495.8%-66.7%71.3%110.0%180.6%5048.1%

Frequently asked questions

What is Novavax’s annual revenue?

$1.1B in fiscal 2025 and $412M over the twelve months to September 30, 2026.

How much profit does Novavax make?

Net income was $440M in fiscal 2025 (net margin 39.2%).

Is Novavax’s revenue growing?

Yes: revenue rose 64.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.